| Previous Close | 118.14 |
| Open | 118.19 |
| Bid | 117.63 x 700 |
| Ask | 120.47 x 700 |
| Day's Range | 118.08 - 118.32 |
| 52 Week Range | 102.07 - 121.24 |
| Volume | 904,339 |
| Avg. Volume | 1,751,750 |
| Net Assets | 35.68B |
| NAV | 115.82 |
| PE Ratio (TTM) | -61.55 |
| Yield | 2.24% |
| YTD Return | 4.53% |
| Beta (3y) | 0.98 |
| Expense Ratio (net) | 0.20% |
| Inception Date | 2000-05-22 |
- Market Realist•23 hours ago
Mylan and Multiple Partnerships to Advance Biosimilar Portfolio
In 2017, Mylan (MYL) plans to submit BLAs to the FDA for the approval of biosimilars for trastuzumab, pegfilgrastim, bevacizumab, adalimumab, and insulin glargine.
- ETF.com•5 days ago
Swedroe: Vanguard Debunks Dividend Myth
Dividend strategies have drawn increasing interest from investors around the world as central banks have pursued both quantitative and qualitative easy monetary policies, keeping interest rates at what have been exceptionally low levels since 2008. But this preference isn’t entirely new; it has long been known many investors have a preference for cash dividends. From the perspective of classical financial theory, this behavior is an anomaly.
- Market Realist•5 days ago
Partnerships, Collaborations to Strengthen Baxter’s IPS Segment
On August 22, 2017, Baxter International entered into a collaboration with ASPEN (American Society for Parenteral and Enteral Nutrition) and launched SmartPN.
